+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 16 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effects of different doses of a new medicine called NNC0519-0130 in people living with chronic kidney disease, some of whom have type 2 diabetes and are overweight or obese. This Phase 2 study also compares NNC0519-0130 to semaglutide, an already prescribed medicine, and a placebo to see how they may improve kidney function. Participants will be randomly assigned to receive once-weekly subcutaneous injections of NNC0519-0130 with a fixed dose escalation until reaching a maintenance dose, semaglutide with a similar dosing schedule, or a placebo matching NNC0519-0130. The treatment period lasts up to 43 weeks with several dosing schemes and groups. During the study, participants will have their kidney function monitored through urine albumin-to-creatinine ratio changes at weeks 12, 24, and 36. Other assessments include estimated glomerular filtration rate, body weight changes, waist circumference, blood pressure, and glycated hemoglobin levels. Safety will be evaluated by tracking adverse events throughout the trial duration. Participants will be regularly assessed to understand the medicines effects and safety.

Age: 18Years +All GendersPhase 2
147 locations
E

Actively Recruiting

Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.

Age: 12Years - 63YearsAll GendersPhase 3
272 locations
S

Actively Recruiting

Researchers are evaluating whether adding erythritol powder during non-surgical periodontal treatment deep cleaning can improve gum health in people with advanced periodontitis stage 3 or 4. The study focuses on individuals with deep gum pockets of 4 mm or more and aims to see if erythritol helps with healing, bleeding, plaque levels, and gum attachment compared to standard treatment alone. The trial is randomized and led by the University of LAquila. Participants receive either standard non-surgical periodontal therapy, which involves scaling and root planing with ultrasonic and manual instruments, or the same treatment combined with sub-gingival air polishing using erythritol powder. Each participant undergoes a single treatment session targeting periodontal pockets of at least 4 mm in depth on non-adjacent teeth. During the study, researchers measure the proportion of gum pockets that successfully close at 2 and 4 months after treatment. They also track bleeding, plaque levels, and gum attachment to assess periodontal health. Factors such as age, sex, smoking status, and diabetes are monitored to understand how they may affect treatment response. Participation involves clinical evaluations and periodontal assessments over the study period ending in late 2025.

Age: 35Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are investigating ischemic stroke cases in patients who are on oral anticoagulants due to atrial fibrillation or other cardioembolic arrhythmias. This observational study, called ASPERA, aims to understand the characteristics of these stroke cases and to evaluate the short- and long-term outcomes of different strategies used to prevent recurrent strokes. The study includes both retrospective and prospective data collection from multiple centers worldwide, coordinated by the University of LAquila. The study has two parts ASPERA-R and ASPERA-P. ASPERA-R collects retrospective data over five years, focusing on baseline demographic, clinical, and neuroimaging features of ischemic strokes in patients on oral anticoagulants. ASPERA-P enrolls patients prospectively for two years with follow-up for five years to assess risks of stroke recurrence and safety events under different secondary prevention approaches, such as continuing or changing oral anticoagulation. Participants will have their data collected at several time points, including hospital admission, discharge, and follow-ups at 90 days, 1 year, and 5 years after stroke. Assessments include clinical evaluations, neuroimaging exams, and monitoring for stroke recurrence, bleeding events, heart attacks, and mortality. The study tracks outcomes to better understand risks and to identify features linked to stroke recurrence and safety events, with total participation lasting up to seven years for prospective patients.

Age: 18Years +All Genders
47 locations
I

Actively Recruiting

Researchers are investigating autoinflammatory diseases AID, which involve recurring inflammatory episodes without infection, cancer, or adaptive immune system problems. This study focuses on both monogenic hereditary periodic syndromes and polygenic or multifactorial AID, including rare conditions like Behets disease, Still disease, Schnitzlers disease, PFAPA syndrome, chronic recurrent multifocal osteomyelitis, non-infectious uveitis and scleritis, among others. The goal is to gather detailed data to improve understanding and management of these rare diseases through an international collaboration. The study uses the AIDA registry, a secure online platform for collecting demographic, genetic, clinical, laboratory, radiologic, and therapeutic information. Data are gathered retrospectively and prospectively during routine clinical visits scheduled every 3-6 months. Eleven registries focus on different AID conditions, enabling comprehensive data collection to identify clinical patterns, treatment impacts, and long-term outcomes over a period of at least 10 years. Participants provide information during their usual care visits, allowing researchers to track changes in disease activity, organ involvement, inflammatory markers, visual function, pain levels, fatigue, fertility, and socioeconomic factors. The study monitors these outcomes over multiple timepoints up to 120 months. Data privacy is ensured by pseudonymizing patient information. This registry supports multiple clinical studies and aims to enhance knowledge, awareness, and future research on autoinflammatory diseases worldwide.

All AgesAll Genders
112 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are studying automated fetal heart function parameters to see if they differ between healthy babies and those with congenital heart disease. This international multicenter observational study aims to find out if these automated measurements can better predict heart complications like hydrops compared to current cardiovascular scores. The study focuses on pregnancies with and without fetal heart defects to compare cardiac function over time. Participants will have two fetal cardiac function ultrasound scans one between 27 weeks and 29 weeks plus 6 days of pregnancy, and another between 34 weeks and 36 weeks plus 6 days. These scans use both clinical and advanced research ultrasound systems to capture detailed heart measurements, including heart size, valve function, blood flow, and contractility. The study collects images and data securely and follows participants until delivery and hospital discharge. During the study, women will undergo standard pregnancy ultrasounds alongside research scans assessing various heart function parameters. Researchers will analyze these detailed images and functional data to compare healthy and affected fetuses. They will also evaluate if adding automated measures improves prediction of complications like hydrops. Data confidentiality is maintained, and results will be published while protecting patient privacy. The entire pregnancy period is observed, with data collected at two specific gestational windows.

Age: 18Years +FEMALE
7 locations
S

Actively Recruiting

This research aims to compare the effects of a new low glucose peritoneal dialysis solution called XyloCore against standard glucose-based solutions in patients with End-Stage Renal Disease ESRD who are undergoing Continuous Ambulatory Peritoneal Dialysis CAPD. The study is randomized, controlled, and open-label with blinded assessment of the main outcomes, conducted over a 6-month period. It includes patients already using common glucose peritoneal dialysis solutions and Extraneal for their long-dwell exchange. Participants will be randomly assigned to receive either the experimental XyloCore solution or continue with their current glucose peritoneal dialysis solutions. XyloCore is provided in low, medium, or high strengths matched to the glucose concentration of the patients prior prescription, while the control group maintains their usual glucose-based solutions. Both groups will continue using Extraneal for the nocturnal long-dwell exchange. Dialysis prescriptions may be adjusted by investigators to meet a target dialysis adequacy measure KtV > 1.7 per week. Throughout the study, participants will undergo regular assessments including measurement of dialysis adequacy total weekly KtVurea, blood tests such as HbA1c, cholesterol levels, hemoglobin, and insulin, as well as monitoring of kidney function, fluid removal, fatigue, and adverse events. The study includes follow-up visits for up to 6 months, with careful monitoring of safety and treatment effects. The trial is sponsored by Iperboreal Pharma Srl and uses centralized randomization with blinded evaluation of primary endpoints.

Age: 18Years +All GendersPhase 3
41 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.

Age: 40Years +All GendersPhase 3
411 locations
O

Actively Recruiting

This research aims to observe and evaluate clinical differences in patients with migraine who receive preventive treatment targeting calcitonin gene-related peptide CGRP or its receptor. The study focuses on monoclonal antibodies erenumab, galcanezumab, fremanezumab, eptinezumab and gepants rimegepant, atogepant over a 2-year observation period. It includes patients who meet local reimbursement criteria and have a confirmed migraine diagnosis following international standards. Participants will start treatment with one of the anti-CGRP monoclonal antibodies or gepants as prescribed. Baseline assessments will be done before treatment begins. Follow-up visits will occur every 6 months to check treatment effectiveness, side effects, patient-reported outcome measures, and eligibility to continue using the study drug. The observation phase will last for 2 years. During the study, participants will undergo regular evaluations including headache frequency, migraine impact, anxiety, depression, sleep quality, and quality of life measures through various questionnaires. Researchers will monitor changes in monthly headache and migraine days, along with other clinical and patient-reported outcomes. The study will ensure ongoing safety and treatment monitoring throughout the 2-year period.

Age: 18Years +All Genders
26 locations
L

Actively Recruiting

Researchers are creating a national registry in Italy for people with Noonan syndrome, a rare genetic condition that can affect growth, the heart, and other parts of the body. Because this condition is uncommon, doctors have limited information about its progression. This study aims to gather detailed data on signs, symptoms, gene changes, growth patterns, health problems, and the effects of growth hormone treatment over time. Doctors at participating centers will securely enter health information of individuals with genetically confirmed Noonan syndrome into an online platform. This includes personal details, medical history, genetic test results, treatments, and heart check results, with follow-up heart evaluations approximately every two years. The registry will include both existing patients and newly diagnosed individuals, with updates over time. Participants will be monitored through their ongoing medical care, with data collected on their health status and treatments. The study will last five years and aims to establish a comprehensive database to help guide long-term care recommendations and support future clinical trials. Participation is voluntary, and no new treatments are tested in this study.

All AgesAll Genders
35 locations

1-10 of 16

1